<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87337">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01889251</url>
  </required_header>
  <id_info>
    <org_study_id>J-12-075</org_study_id>
    <nct_id>NCT01889251</nct_id>
  </id_info>
  <brief_title>A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the superiority of a single intravitreal injection
      of A01016 compared to sham-injection in subjects with symptomatic vitreomacular adhesion
      (VMA).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of Subjects with Non-Surgical Resolution of Vitreomacular Adhesion</measure>
    <time_frame>Day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>As determined by masked Central Reading Center (CRC) Spectral Domain Optical Coherence Tomography (SD-OCT)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Vitreomacular Adhesion</condition>
  <arm_group>
    <arm_group_label>A01016</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A01016 administered as a single intravitreal injection to the study eye at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham injection</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Single sham injection to the study eye at baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A01016</intervention_name>
    <arm_group_label>A01016</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham injection</intervention_name>
    <arm_group_label>Sham injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic vitreomacular adhesion (VMA) which, in the opinion of the Investigator,
             is related to decreased visual function;

          -  Best corrected visual acuity (BCVA) of 20/25 or worse in the study eye;

          -  BCVA of 20/800 or better in the non-study eye;

          -  Provide written informed consent;

          -  Follow specified instructions during study period;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Evidence of proliferative retinopathy, exudative age-related macular degeneration, or
             retinal vein occlusion in the study eye;

          -  Vitreous hemorrhage or other opacification;

          -  High myopia in the study eye;

          -  Ocular surgery, laser photocoagulation treatment, or intravitreal injection(s) in the
             study eye in the prior 3 months;

          -  Uncontrolled glaucoma in the study eye;

          -  History of retinal detachment in either eye;

          -  Active infection in either eye;

          -  Pregnant or of child-bearing potential and not utilizing acceptable form of
             contraception;

          -  Participation in another investigational drug study within 30 days prior to this
             study;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atsushi Morishima</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Japan, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Alcon for Trial Locations</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 28, 2014</lastchanged_date>
  <firstreceived_date>June 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitreomacular Adhesion</keyword>
  <keyword>Vitreomacular Traction</keyword>
  <keyword>Vitreomacular Traction Syndrome</keyword>
  <keyword>Vitrectomy</keyword>
  <keyword>Central Visual Field Defect</keyword>
  <keyword>Blind Spot</keyword>
  <keyword>Intravitreal Injection</keyword>
  <keyword>Macula</keyword>
  <keyword>Retina</keyword>
  <keyword>Decreased Visual Acuity</keyword>
  <keyword>Visual Complaint</keyword>
  <keyword>SD-OCT</keyword>
  <keyword>Macular Hole</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
